Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. (original) (raw)

Research Article Free access | 10.1172/JCI3125

K Balashov, S Issazadeh, D Smith, H L Weiner, and S J Khoury

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Find articles by Comabella, M. in:JCI |PubMed |Google Scholar

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Find articles by Balashov, K. in:JCI |PubMed |Google Scholar

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Find articles by Issazadeh, S. in:JCI |PubMed |Google Scholar

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Find articles by Smith, D. in:JCI |PubMed |Google Scholar

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Find articles by Weiner, H. in:[JCI](/search/results?q=author.first%5Fname%3A%22H L%22+author.last%5Fname%3A%22Weiner%22&search%5Ftype=advanced) |PubMed |Google Scholar

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Find articles by Khoury, S. in:[JCI](/search/results?q=author.first%5Fname%3A%22S J%22+author.last%5Fname%3A%22Khoury%22&search%5Ftype=advanced) |PubMed |Google Scholar

Published August 15, 1998 -More info

Published August 15, 1998 -Version history

View PDF

Abstract

Multiple sclerosis is postulated to be a Th1-type cell-mediated autoimmune disease. We investigated cytokine profiles in patients with progressive multiple sclerosis by using intracytoplasmic staining. We found increased IL-12 production by monocytes and increased IFN-gamma production by T cells in untreated patients as compared with controls. In patients treated with methotrexate, methylprednisolone, or cyclophosphamide/methylprednisolone (CY/MP), only CY/MP treatment normalized the elevated IL-12 production. Furthermore, CY/MP-treated patients had decreased IFN-gamma and increased IL-4, IL-5, and TGF-beta expression. Patients followed prospectively before and after starting CY/MP treatment showed a gradual decrease in IL-12 and IFN-gamma production and an increase in IL-4 and IL-5. In vitro, addition of 4-hydroperoxycyclophosphamide, a metabolite of cyclophosphamide decreased IL-12 production in mononuclear cell cultures. When patients were classified as having active or stable disease, IL-12 production correlated with disease activity. In summary, our results demonstrate a Th1-type cytokine bias in peripheral blood mononuclear cells of untreated progressive MS patients that is reversed by CY/MP treatment and is associated with Th2 and TGF-beta (Th3) type responses. These findings provide a basis for immune monitoring of patients with MS and suggest that treatments that downregulate IL-12 may prove to be beneficial in progressive MS.

Version history